SCHEMBL1367264

SCHEMBL1367264

COc1ccc(/C=C\C(=O)c2cc3ccc(Cl)cc3[nH]c2=O)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PADI4 Q9UM07 2/20 0.76
MAOB P27338 6/20 0.55
ABCG2 Q9UNQ0 6/20 0.55
MAOA P21397 1/20 0.54
PDGFRB P09619 1/20 0.54
FLT3 P36888 1/20 0.54
ACHE P22303 1/20 0.52
BACE1 P56817 1/20 0.52
MAPT P10636 4/20 0.50
MEN1 O00255 3/20 0.50
MAPK1 P28482 3/20 0.50
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 3/20 0.50
LMNA P02545 2/20 0.50
CYP3A4 P08684 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 2/20 0.50
APP P05067 1/20 0.50
CYP2C19 P33261 1/20 0.50
TNFRSF1A P19438 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367265 1.00 PADI4 (0.76) PADI4MAOBABCG2MAOAPDGFRB
SCHEMBL4347009 1.00 PADI4 (0.76) PADI4MAOBABCG2MAOAPDGFRB
SCHEMBL31139822 0.92 PADI4 (0.73) PADI4MAOBABCG2MAOAPDGFRB
SCHEMBL1368520 0.90 PADI4 (0.58) PADI4MAOBABCG2MAOAMAPT
SCHEMBL1367712 0.90 PADI4 (0.58) PADI4MAOBABCG2MAOAMAPT
SCHEMBL1367713 0.90 PADI4 (0.58) PADI4MAOBABCG2MAOAMAPT
SCHEMBL1368142 0.86 PADI4 (0.57) PADI4MAOBABCG2MAOAPDGFRB
SCHEMBL1368309 0.86 PADI4 (0.57) PADI4MAOBABCG2MAOAPDGFRB
SCHEMBL1368149 0.86 PADI4 (0.57) PADI4MAOBABCG2MAOAPDGFRB
SCHEMBL1369067 0.86 PADI4 (1.00) PADI4MAOBABCG2MAOAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS PADI4 3091/4885MAOB 2929/4885ABCG2 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.